Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes

Journal of Immune Based Therapies and Vaccines

Volumn 1, Issue , 2003, Pages

  Andersen, Marie Louise ^a   Ruhwald, Morten ^a   Thorn, Mette ^a   Pedersen, Anders Elm ^a   Mathiassen, Susanne ^a   Buus, Soren ^a   Claesson, Mogens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

mRNA microassay; p53; Peptide; Tumor associated antigens; Vaccination

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; MESSENGER RNA; PEPTIDE DERIVATIVE; PROTEIN P53; RAD50 PROTEIN; T LYMPHOCYTE ANTIBODY; TUMOR ANTIGEN; TUMOR REJECTION ANTIGEN; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; THYMOMA; TUMOR CELL; TUMOR GROWTH; VACCINATION;

EID: 1542279368     PISSN: 14768518     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-8518-1-1     Document Type: Article

References (21)

1. Offringa R, van der Burg SH, Ossendorp F, Toes REM and Melief CJM Design and evaluation of antigen-specific vaccine strategies against cancer. Curr Opin Immunol 2000, 12:576-582
2. Jager E, Bernhard H, Romero P, Ringhoffer M, Arand M and Karbach J Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996, 66:162-169
3. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT and Mukherji B Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cellbased vaccine. Cancer Res 1996, 56:2479-83
4. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G and Marty V Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999, 5:2756-65
5. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM and Topalian SL Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-7
6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S and Dummer R Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-32
7. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B and Tessier MH Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-30
8. Mathiassen S, Lauemøller SL, Ruhwald M, Claesson MH and Buus S Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur J Immunol 2001, 31:1239-1246
9. Paull TT and Gellert M Nbs1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. Genes Dev 1999, 13:1276-88
10. Leach DR, Krummel MF and Allison JP Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-6
11. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R and Allison JP Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med 2001, 194:481-92
12. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R and Melief CJ Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-32
13. Andersen ML, Ruhwald M, Nissen MH, Buus S and Claesson MH Self peptides of intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol
14. Milich DR, Hughes JL, McLachlan A, Thornton GB and Moriarty A Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci USA 1988, 85:1610-14
15. Blaszczyk-Thurin M, Ertl IO and Ertl HCJ An experimental vaccine expression wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogeneous p53. Scand J Immunol 2002, 56:361-375
16. Hurwitz AA, Yu TF, Leach DR and Allison JP CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998, 95:10067-71
17. Offringa R, Vierboom MPM, van der Burg SH, Erdile L and Melief CJM P53: A potential target antigen for immunotherapy of cancer. Ann NY Acad Sci 2000, 910:223-33
18. Diehl L, Den Boer AT, van der Voort EI, Melief CJM, Offringa R and Toes RE The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med 2000, 78:363-7
19. Ohlen C, Bastin OC, Ljunggren HG, Imreh S, Klein G, Towsend AR and Kärre K Restoration of H-2b expression and processing of endogeneous antigens in the MHC-I pathway by fusion of lymphoma mutant to L cells of the H-2k haplotype. Eur J Immunol 1990, 18:3-6
20. Claesson MH, Hansen BU, Irik J, Østergaard L, Skov S and Buus S Antibodies directed against monomorphic and evolutionary conserved self epitopes can be generated in "knock-out" animals. Scand J Immunol 1994, 40:257-264
21. Krummel MF and Allison JP CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465